ConductScience.org, home

Disease · MONDO_0006668

Comparisons in its trials42

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Moxifloxacin AF vs Vehicle: deaths from any cause0 of 5930 of 5861,179NCT00759148Trial comparisons
Moxifloxacin AF vs Vehicle: serious adverse events0 of 5930 of 5861,179NCT00759148Trial comparisons
Moxifloxacin Solution vs Besifloxacin Suspension: serious adverse events1 of 5791 of 5821,161NCT00348348Trial comparisons
Moxifloxacin vs Ofloxacin: serious adverse events1 of 4890 of 493982NCT01573910Trial comparisons
ISV-403 vs Vehicle: serious adverse events1 of 4421 of 432874NCT00347932Trial comparisons
Gatifloxacin 0.5% Eye Drops vs Placebo Eye Drops: serious adverse events2 of 4290 of 427856NCT00518089Trial comparisons
AzaSite vs Tobramycin: serious adverse events0 of 3650 of 378743NCT00105469Trial comparisons
AzaSite vs Vehicle: serious adverse events0 of 3332 of 350683NCT00105534Trial comparisons
Gatifloxacin 0.5% Eye Drops vs Placebo Eye Drops: serious adverse events0 of 2881 of 289577NCT00509873Trial comparisons
Moxifloxacin Solution vs Besifloxacin Suspension: Clinical Resolution167 of 281147 of 252533NCT00348348Trial comparisons
Moxifloxacin Solution vs Besifloxacin Suspension: Microbial Eradication238 of 281220 of 252533NCT00348348Trial comparisons
Moxifloxacin Solution vs Besifloxacin Suspension: Clinical Resolution236 of 281213 of 252533NCT00348348Trial comparisons
Moxifloxacin Solution vs Besifloxacin Suspension: Microbial Eradication256 of 281235 of 252533NCT00348348Trial comparisons
Besifloxacin vs Vehicle: serious adverse events0 of 2280 of 236464NCT00972777Trial comparisons
ISV-403 vs Vehicle: Clinical Resolution of Baseline Bacterial Conjunctivitis90 of 19963 of 191390NCT00347932Trial comparisons
ISV-403 vs Vehicle: Microbial Eradication of Baseline Bacterial Infection176 of 199137 of 191390NCT00347932Trial comparisons
ISV-403 vs Vehicle: Clinical Resolution of Baseline Bacterial Conjunctivitis168 of 199132 of 191390NCT00347932Trial comparisons
ISV-403 vs Vehicle: Microbial Eradication of Baseline Bacterial Infection182 of 199114 of 191390NCT00347932Trial comparisons
AzaSite vs Tobramycin: Number of Participants Who Achieved Clinical Resolution at Visit 3127 of 159123 of 157316NCT00105469Trial comparisons
AzaSite vs Tobramycin: Number of Participants Who Achieved Bacterial Eradication at Visit 3140 of 159148 of 157316NCT00105469Trial comparisons

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006668/comparisons